Ergomed is proud to announce its contribution to a major advancement in oncology research through the successful delivery of the IT-MATTERS study, one of the largest Head and Neck cancer clinical trials ever conducted globally.
The scientific publication, titled “Neoadjuvant Leukocyte Interleukin Injection Immunotherapy Improves Overall Survival in Low-risk Locally Advanced Head and Neck Squamous Cell Carcinoma – The IT-MATTERS Study”, was recently published in the peer-reviewed journal Pathology & Oncology Research and Frontiers.
Ergomed’s Vice President of Global Medical Affairs, Dr. Dusan Markovic, is a co-author of the publication, underscoring Ergomed’s scientific and operational leadership in complex oncology trials.
“This publication highlights our long-standing commitment to advancing oncology research and our proven capabilities in managing large-scale, global trials in rare and complex cancers,” said Dr. Markovic.